Freitag, 29. März 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study

Rekrutierend

NCT-Nummer:
NCT04717739

Studienbeginn:
Dezember 2021

Letztes Update:
10.01.2023

Wirkstoff:
-

Indikation (Clinical Trials):
Glioblastoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
NovoCure Ltd.

Collaborator:
-

Studienleiter

Martin Glas, Prof.
Principal Investigator
University hospital Essen, Essen, Germany

Kontakt

Studienlocations
(3 von 36)

Universitätsklinikum Aachen
52074 Aachen
GermanyAktiv, nicht rekrutierend» Google-Maps
Universitätsklinikum Bonn
53127 Bonn
(Nordrhein-Westfalen)
GermanyAktiv, nicht rekrutierend» Google-Maps
Darmkrebszentrum Klinikum Chemnitz
Flemmingstraße 2
9116 Chemnitz
DeutschlandAktiv, nicht rekrutierend» Google-Maps
Sana Kliniken Duisburg
47055 Duisburg
(Nordrhein-Westfalen)
GermanyAktiv, nicht rekrutierend» Google-Maps
Universitätsklinikum Düsseldorf HHU
40225 Düsseldorf
(Nordrhein-Westfalen)
GermanyAktiv, nicht rekrutierend» Google-Maps
Universitätsklinikum Frankfurt Goethe-Universität
60528 Frankfurt
(Hessen)
GermanyAktiv, nicht rekrutierend» Google-Maps
Interdisziplinäres Brustzentrum der Universitätsmedizin Greifswald
Ferdinand-Sauerbruch-Straße
17475 Greifswald Greifswald
(Mecklenburg-Vorpommern)
DeutschlandAktiv, nicht rekrutierend» Google-Maps
Leberkrebszentrum Medizinische Hochschule Hannover
Carl-Neuberg-Straße 1
30625 Hannover
DeutschlandAktiv, nicht rekrutierend» Google-Maps
Universitäts-Brustzentrum am Universitätsklinikum des Saarlandes
Kirrberger Straße 100
66424 Homburg
DeutschlandAktiv, nicht rekrutierend» Google-Maps
Universitätsklinikum Jena
07747 Jena
(Thüringen)
GermanyAktiv, nicht rekrutierend» Google-Maps
IBZ - Interdisziplinäres Brustzentrum am Klinikum Kassel
Mönchebergstraße 41-43
34125 Kassel
(Hessen)
DeutschlandAktiv, nicht rekrutierend» Google-Maps
Lungenkrebszentrum Uniklinik Köln / Solingen
Kerpener Straße 62
50937 Köln
DeutschlandAktiv, nicht rekrutierend» Google-Maps
Kliniken der Stadt Köln GmbH
51109 Köln
(Nordrhein-Westfalen)
GermanyAktiv, nicht rekrutierend» Google-Maps
Otto-von-Guericke-Universität Magdeburg
39120 Magdeburg
(Sachsen-Anhalt)
GermanyAktiv, nicht rekrutierend» Google-Maps
Med. Fakultät Mannheim der Universität Heidelberg
68167 Mannheim
(Baden-Württemberg)
GermanyAktiv, nicht rekrutierend» Google-Maps
Johannes Wesling Klinikum Minden
32429 Minden
(Nordrhein-Westfalen)
GermanyAktiv, nicht rekrutierend» Google-Maps
Interdisziplinäres Brustzentrum Klinikum Nürnberg
Prof.-Ernst-Nathan-Straße 1
90419 Nürnberg
(Bayern)
DeutschlandAktiv, nicht rekrutierend» Google-Maps
Pius-Hospital Oldenburg
26121 Oldenburg
(Niedersachsen)
GermanyAktiv, nicht rekrutierend» Google-Maps
Niels-Stensen-Kliniken - Marienhospital Osnabrück
49076 Osnabrück
(Niedersachsen)
GermanySchwebend» Google-Maps
Pankreaskarzinomzentrum der Universitätsmedizin Rostock
Doberaner Straße 137-139
18057 Rostock
DeutschlandAktiv, nicht rekrutierend» Google-Maps
HELIOS Kliniken Schwerin GmbH
19049 Schwerin
(Mecklenburg-Vorpommern)
GermanyAktiv, nicht rekrutierend» Google-Maps
Viszeralonkologisches Zentrum Universitätsklinikum Tübingen
Hoppe-Seyler-Straße 3
72076 Tübingen
DeutschlandAktiv, nicht rekrutierend» Google-Maps
Paracelsus-Klinik Zwickau
08008 Zwickau
(Sachsen)
GermanyAktiv, nicht rekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

Glioblastoma (GBM) is the most common malignant primary tumor of the brain with an annual

incidence of approximately 3/100.000. Since 2005 the treatment for newly diagnosed GBM

consisted of maximal surgical resection, approx. 60 Gy of radiotherapy together with

chemotherapy using temozolomide (TMZ), followed by 6 cycles of maintenance chemotherapy. This

treatment regimen demonstrated increased median overall survival (OS) from 12.1 to 14.6

months in comparison to surgery and radiotherapy alone in 2005.

Since 2005, despite plenty of clinical phase III trials conducted, Tumor Treating Fields

(TTFields) therapy was the first treatment shown to significantly increase median

progression-free survival (PFS), OS and one to five year survival rates compared to the

previous standard of care. These results led to FDA approval of TTFields for newly diagnosed

GBM and were acknowledged since then by several guidelines recommending TTFields for GBM

therapy (e.g. NCCN guidelines for CNS cancers V.1.2018, RCC guideline tumörer I hjärna och

ryggmärg 2020-01-14 V3.0, DGHO guideline for glioma in adults ICD-10 C71 March 2019). Today,

several national committees in Europe already list TTFields as reimbursed treatment (e.g.

Austria, Sweden, Germany).

Data with TTFields therapy in real-world setting is limited and therefore further evaluation

of different treatment aspects of TTFields therapy in clinical routine are of interest. In

particular the QoL-related aspects neurocognitive functioning, daily activity and sleep

quality in this patient cohort is of major interest, given the limited life expectancy with

this disease.

This non-interventional study aims to investigate change over time in neurocognitive

functioning, sleep quality, and activity in daily life as important determinants of QoL in a

large cohort of GBM patients in Germany treated with TTFields in routine clinical care using

low-threshold, electronic PRO and modern automated tracking data analyses. The gained results

will allow even better understanding of TTFields therapy in daily life of GBM patients and

consequently, better informing patients about what to expect when starting this therapy,

increasing therapy compliance even further in the long-term.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- min.18 years of age

- Newly diagnosed, histologically confirmed GBM

- Patient after completion of radiochemotherapy but within first 3 cycles of first-line

tumor-specific maintenance chemotherapy

- Clinical indication of treatment with NovoTTF-200A System (Optune®) according to IFU

and medical guidelines

- Signed informed consent

Exclusion Criteria:

Any foreseeable deviation from the IFU of NovoTTF-200T Device

Studien-Rationale

Primary outcome:

1. Time of usage of TTFields treatment in follow-up derived from monitoring data of the devices, standardised to usage days, as measure of compliance with TTFields treatment. (Time Frame - through study completion, an average of 18 months (mean follow-up time)):
Time of usage (compliance) of TTFields treatment over time is measured using the treatment compliance report at the Follow-up period

2. Number of TTFields treatment-related SAEs as assessed by the CEC standardized to one year of FU time (Time Frame - through study completion, an average of 18 months (mean follow-up time)):
Number of TTFields treatment-related SAEs standardized to one year of follow-up (FU) is measured using the collection of SAEs during the follow-up period

3. Changes in daily physical activity as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy (Time Frame - Up to 4 months after start of TTFields treatment compared to baseline):
Changes in daily physical activity will be assessed by smartphone app-based clinical monitoring.

4. Changes in sleep quality as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy (Time Frame - Up to 4 months after start of TTFields treatment compared to baseline):
Changes in sleep quality will be assessed by smartphone app-based clinical monitoring.

5. Changes in neurocognitive functioning as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy. (Time Frame - Up to 4 months after start of TTFields treatment compared to baseline):
Changes in neurocognitive functioning will be assessed by means of MoCA interview tests.

Geprüfte Regime

  • TTFields:
    Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.